Profile data is unavailable for this security.
About the company
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceutical’s products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies Paracetamol, Metformin, Guaifenesin, and Methocarbamol APIs. It has over seven manufacturing facilities, approximately six of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. The Company’s wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
- Revenue in INR (TTM)44.78bn
- Net income in INR4.87bn
- Incorporated1991
- Employees4.12k
- LocationGranules India Ltd2nd Floor3rd Block, My Home Hub MadhapurHYDERABAD 500081IndiaIND
- Phone+91 4 069043500
- Fax+91 4 023115145
- Websitehttps://granulesindia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orchid Pharma Ltd | 9.05bn | 1.20bn | 74.94bn | 872.00 | 61.68 | 6.12 | 48.92 | 8.28 | 23.96 | 23.96 | 181.23 | 241.38 | 0.5787 | 1.96 | 4.49 | 10,376,120.00 | 7.57 | -0.9734 | 9.09 | -1.40 | 41.26 | 40.74 | 13.09 | -2.40 | 1.82 | 6.74 | 0.1187 | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| F D C Ltd | 20.72bn | 3.17bn | 79.04bn | 6.66k | 25.08 | 3.45 | 21.85 | 3.81 | 19.36 | 19.36 | 126.27 | 140.76 | 0.824 | 2.16 | 12.48 | 3,112,058.00 | 12.59 | 12.05 | 14.46 | 13.73 | 65.35 | 61.54 | 15.27 | 15.85 | 2.49 | 72.53 | 0.0087 | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Procter & Gamble Health Ltd | 11.60bn | 2.18bn | 84.98bn | 1.34k | 39.05 | -- | 34.77 | 7.33 | 131.10 | 131.10 | 698.14 | -- | -- | -- | -- | 8,680,689.00 | -- | -- | -- | -- | 71.42 | -- | 18.77 | -- | -- | 441.58 | -- | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| Blue Jet Healthcare Ltd | 7.22bn | 1.68bn | 91.46bn | 447.00 | 54.49 | 9.90 | 47.75 | 12.67 | 9.68 | 9.68 | 41.61 | 53.27 | 0.6732 | 1.97 | 3.46 | 16,149,080.00 | 15.66 | -- | 19.57 | -- | 55.65 | -- | 23.26 | -- | 2.51 | 131.95 | 0.0012 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Shilpa Medicare Ltd | 12.15bn | 610.83m | 91.53bn | 931.00 | 140.43 | 3.93 | 53.86 | 7.54 | 6.67 | 6.67 | 132.68 | 238.05 | 0.3969 | 1.24 | 3.40 | 13,047,900.00 | 2.00 | 2.84 | 2.44 | 3.65 | 66.38 | 60.08 | 5.04 | 7.03 | 1.08 | 1.79 | 0.1746 | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Akums Drugs and Pharmaceuticals Ltd | 40.79bn | 2.78bn | 95.96bn | 7.39k | 33.38 | 3.29 | 22.97 | 2.35 | 18.26 | 18.26 | 272.23 | 185.07 | 1.04 | 3.77 | 3.94 | 5,521,446.00 | 7.20 | -- | 11.08 | -- | 37.76 | -- | 6.95 | -- | 1.59 | 2.23 | 0.1571 | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Sanofi Consumer Healthcare India Ltd | -100.00bn | -100.00bn | 110.51bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Granules India Ltd | 44.78bn | 4.87bn | 132.05bn | 4.12k | 27.13 | 3.85 | 18.92 | 2.95 | 20.08 | 20.08 | 184.59 | 141.41 | 0.8372 | 1.36 | 5.14 | 10,863,290.00 | 9.11 | 10.68 | 14.05 | 16.18 | 59.39 | 48.83 | 10.88 | 11.82 | 0.7152 | 6.88 | 0.2425 | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Glenmark Life Sciences Ltd | 22.05bn | 4.24bn | 132.34bn | 2.01k | 31.34 | 5.21 | 27.53 | 6.00 | 34.47 | 34.47 | 179.44 | 207.17 | 0.7304 | 1.46 | 2.79 | 10,947,850.00 | 14.03 | 18.28 | 16.69 | 29.99 | 54.92 | 53.40 | 19.21 | 20.23 | 3.03 | 380.55 | 0.0063 | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Strides Pharma Science Ltd | 44.10bn | 1.77bn | 138.27bn | 3.07k | 78.24 | 6.08 | 37.20 | 3.14 | 19.22 | 25.15 | 479.84 | 247.16 | 0.7155 | 1.50 | 3.57 | 14,389,290.00 | 2.79 | -1.68 | 5.43 | -2.97 | 60.19 | 51.39 | 3.91 | -3.36 | 0.6355 | 1.52 | 0.5103 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Sanofi India Ltd | 21.92bn | 3.60bn | 139.95bn | 2.17k | 38.86 | -- | 35.22 | 6.38 | 156.36 | 199.60 | 951.86 | -- | -- | -- | -- | 10,083,720.00 | -- | 22.42 | -- | 30.21 | 53.94 | 55.52 | 16.43 | 21.03 | -- | 348.40 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Marksans Pharma Ltd | 23.79bn | 3.47bn | 140.10bn | 2.00k | 40.35 | 6.14 | 32.55 | 5.89 | 7.66 | 7.66 | 52.53 | 50.34 | 0.9105 | 1.65 | 4.75 | 11,893,400.00 | 13.30 | 14.62 | 15.78 | 18.52 | 55.32 | 50.52 | 14.61 | 14.03 | 2.97 | 31.25 | 0.0792 | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Caplin Point Laboratories Ltd | 18.31bn | 4.94bn | 147.68bn | 859.00 | 30.02 | 5.81 | 26.38 | 8.07 | 64.73 | 64.73 | 240.10 | 334.54 | 0.6861 | 2.28 | 3.40 | 21,312,920.00 | 18.62 | 19.83 | 21.36 | 22.82 | 58.72 | 53.38 | 27.14 | 25.39 | 5.07 | 932.86 | 0.0009 | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Astrazeneca Pharma India Ltd | 14.85bn | 819.20m | 157.64bn | 940.00 | 192.45 | 23.20 | 153.62 | 10.62 | 32.76 | 32.76 | 593.93 | 271.74 | 1.27 | 2.52 | 10.63 | 15,792,680.00 | 6.99 | 11.78 | 11.44 | 19.62 | 44.88 | 54.64 | 5.52 | 10.27 | 1.44 | 134.82 | 0.0246 | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Jubilant Pharmova Ltd | 69.20bn | 5.93bn | 179.04bn | 995.00 | 30.24 | 3.01 | 18.52 | 2.59 | 37.38 | 37.38 | 436.41 | 375.04 | 0.5934 | 1.75 | 8.15 | 69,544,720.00 | 5.05 | 2.96 | 6.01 | 3.55 | 68.50 | 68.47 | 8.51 | 5.13 | 1.20 | 2.51 | 0.342 | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Eris Lifesciences Ltd | 24.98bn | 3.48bn | 186.04bn | 3.08k | 53.45 | 6.71 | 29.87 | 7.45 | 25.57 | 25.57 | 183.35 | 203.74 | 0.4585 | 2.90 | 5.96 | 8,110,753.00 | 6.73 | 13.42 | 8.39 | 16.80 | 77.03 | 79.98 | 14.69 | 24.96 | 0.8599 | 3.41 | 0.4626 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Data as of Nov 22 2024. Currency figures normalised to Granules India Ltd's reporting currency: Indian Rupee INR
18.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Singapore) Ltd.as of 30 Sep 2024 | 8.08m | 3.33% |
| Axis Asset Management Co. Ltd.as of 31 Oct 2024 | 6.95m | 2.87% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 5.58m | 2.30% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 5.09m | 2.10% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 4.48m | 1.85% |
| Schroder Investment Management Ltd.as of 31 Jul 2024 | 4.18m | 1.73% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 2024 | 3.21m | 1.32% |
| AllianceBernstein LPas of 30 Sep 2024 | 2.98m | 1.23% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 2.79m | 1.15% |
| Tata Asset Management Pvt Ltd.as of 31 Oct 2024 | 2.65m | 1.10% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
